Somatic Cell Nuclear Transfer Oocyte Activation for Stable hPSCs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating immunocompatible and patient-specific human pluripotent stem cells (hPSCs) through parthenogenesis and somatic cell nuclear transfer (SCNT) face significant limitations, including low success rates in blastocyst formation, aneuploidy, and karyotype instability, which hinder their practical clinical application.
Innovation Solution
The use of improved techniques such as real-time visualization with poloscope microscopy, methylation-altering agents, and the addition of mitotic structures like centrioles from sperm derivatives to enhance oocyte activation and blastocyst expansion, along with the use of specific compounds in activation and post-activation media, to promote genomic activation and stability of hPSCs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional parthenogenesis or SCNT techniques are used to generate patient-specific hPSCs, then immunocompatibility and patient-specificity are achieved, but success rates in blastocyst formation are very low (less than 10% of donor oocytes)
Solution Approach 1:
The patent applies preliminary action by pre-treating oocytes with specific compounds (such as calcium ionophores, protein phosphatase inhibitors, or other activation agents) before attempting parthenogenesis or SCNT. This pre-activation preparation improves the likelihood of successful blastocyst formation by priming the oocyte for proper developmental progression, thereby increasing both reliability and productivity of hPSC generation.
Solution Approach 2:
The patent employs parameter changes by optimizing cultural conditions, chemical treatments, and procedural parameters during oocyte activation and early embryonic development. By adjusting factors such as calcium concentration, pH, temperature, and exposure times to specific optimal values, the method increases blastocyst formation rates from less than 10% to significantly higher yields, directly resolving the contradiction between reliability and productivity.
2Reliability
If conventional techniques are used for oocyte activation and blastocyst formation, then some hPSC lines can be generated, but aneuploidy and karyotype instability occur
Solution Approach 1:
The patent implements feedback mechanisms by monitoring developmental progression through specific markers and morphological assessments at critical stages. This allows for real-time identification and exclusion of embryos showing signs of aneuploidy or abnormal development, ensuring that only genetically stable hPSC lines are generated and expanded, thus maintaining high reliability while preserving productivity through selective optimization.
Solution Approach 2:
The patent applies preliminary genetic screening and selection methods before full hPSC line establishment. By performing preliminary assessments of chromosomal integrity and developmental potential early in the process, the method prevents propagation of aneuploid lines, thereby ensuring genetic stability without significantly reducing the overall yield of usable hPSC lines.
3Productivity
If more donor oocytes are used to compensate for low success rates, then more hPSC lines can be generated, but the complexity and cost of the procedure increase
Solution Approach 1:
The patent applies universality by developing a standardized, multi-purpose protocol that can be applied to both parthenogenesis and SCNT approaches using the same activation treatments and cultural conditions. This universal method reduces procedural complexity by eliminating the need for separate optimized protocols for different techniques, thereby increasing productivity without proportionally increasing device or procedural complexity.
Solution Approach 2:
The patent uses parameter changes to create optimized cultural conditions that significantly improve blastocyst formation rates. By establishing specific optimal parameters for activation agents, incubation conditions, and media composition, the method achieves high productivity with a manageable level of procedural complexity, as the optimized parameters can be systematically applied without requiring overly complex equipment or procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These techniques significantly improve the efficiency and stability of generating immunocompatible and patient-specific hPSCs, allowing for the creation of banks of pluripotent cells that are genetically and epigenetically stable, and capable of differentiating into various cell types, thus enhancing their suitability for clinical applications.
Implementation Method 1
the activation medium includes a calcium ionophore
Implementation Method 2
methylation-altering agents, and the addition of mitotic structures like centrioles
Data Source
AI summary
Immunocompatible pluripotent stem cells (pSCs), which include cells compatible with different patient populations or patient-specific cells, find wide application in regenerative medicine therapies. Described herein are immunocompatible pSCs generated using techniques such as parthenogenesis resulting in cells possessing desired haplotypes of reduced zygosity, antigenically compatible with multiple patient populations, or nuclear transfer allowing generation of patient-specific cells. Methods described herein related to parthenogenesis, nuclear transfer, or pSC cell line generation. Also described herein are compositions of immunocompatible pSCs and cell lines generated by the aforementioned techniques.